Literature DB >> 25448984

MiR-185 is involved in human breast carcinogenesis by targeting Vegfa.

Rui Wang1, Shi Tian, Hong-Bin Wang, Da-Peng Chu, Jing-Li Cao, Hong-Fei Xia, Xu Ma.   

Abstract

MiR-185 expression has been associated with many cancers. However, the roles of miR-185 in human breast cancer remain elusive. Here, we found that miR-185 expression was decreased in human breast cancer tissues compared with healthy tissue controls. Up-regulation of miR-185 inhibited breast cancer cell proliferation and invasion and vice versa. MiR-185 was shown to bind to the 3′-untranslated region (UTR) of vascular endothelial growth factor a (Vegfa), and a significant inverse correlation was found between miR-185 and Vegfa. Vegfa overexpression partially restored the inhibition of cell proliferation and invasion that was induced by miR-185, and vice versa. Additionally, Vegfa expression was found to be high in human breast cancer tissues. Thus, miR-185-mediated Vegfa targeting may be involved in breast cancer formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25448984     DOI: 10.1016/j.febslet.2014.09.045

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  Downregulation of miR-1266-5P, miR-185-5P and miR-30c-2 in prostatic cancer tissue and cell lines.

Authors:  Shiva Ostadrahimi; Shima Fayaz; Monireh Parvizhamidi; Manuchehr Abedi-Valugerdi; Moustapha Hassan; Mehdi Kadivar; Ladan Teimoori-Toolabi; Mojgan Asgari; Hossein Shahrokh; Maryam Abolhasani; Reza Mahdian; Pezhman Fard-Esfahani
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

3.  Regulatory role of microRNA-185 in the recovery process after ankle fracture.

Authors:  Deping Sun; Juntao Liu; Qingpeng Shi; Haibo Mu; Dongsheng Zhou
Journal:  Exp Ther Med       Date:  2018-07-27       Impact factor: 2.447

4.  miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas.

Authors:  Nicla Borrelli; Maria Denaro; Clara Ugolini; Anello Marcello Poma; Mario Miccoli; Paolo Vitti; Paolo Miccoli; Fulvio Basolo
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

Review 5.  Noncoding RNAs in breast cancer.

Authors:  Pang-Kuo Lo; Benjamin Wolfson; Xipeng Zhou; Nadire Duru; Ramkishore Gernapudi; Qun Zhou
Journal:  Brief Funct Genomics       Date:  2015-12-18       Impact factor: 4.241

6.  microRNA-497 overexpression decreases proliferation, migration and invasion of human retinoblastoma cells via targeting vascular endothelial growth factor A.

Authors:  Jianjun Li; Yinghui Zhang; Xiuchao Wang; Ruibo Zhao
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

Review 7.  A step-by-step microRNA guide to cancer development and metastasis.

Authors:  Georgios S Markopoulos; Eugenia Roupakia; Maria Tokamani; Evangelia Chavdoula; Maria Hatziapostolou; Christos Polytarchou; Kenneth B Marcu; Athanasios G Papavassiliou; Raphael Sandaltzopoulos; Evangelos Kolettas
Journal:  Cell Oncol (Dordr)       Date:  2017-07-26       Impact factor: 6.730

8.  miR-185 silencing promotes the progression of atherosclerosis via targeting stromal interaction molecule 1.

Authors:  Ming Fang; Yanfei Li; Yingbiao Wu; Zhongping Ning; Xuejun Wang; Xinming Li
Journal:  Cell Cycle       Date:  2019-03-20       Impact factor: 4.534

9.  MicroRNA-185 regulates spinal cord injuries induced by thoracolumbar spine compression fractures by targeting transforming growth factor-β1.

Authors:  Pengfei Zhao; Shaochun Wang; Yingjie Zhou; Huailiang Zheng; Gang Zhao
Journal:  Exp Ther Med       Date:  2017-01-17       Impact factor: 2.447

10.  MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells.

Authors:  Shuai Li; Yulian Ma; Xinfang Hou; Ying Liu; Ke Li; Shuning Xu; Jufeng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.